Compare Seikagaku Corp. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
JPY 41,929 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.18
-0.83%
0.57
Revenue and Profits:
Net Sales:
9,711 Million
(Quarterly Results - Mar 2026)
Net Profit:
354 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.08%
0%
-8.08%
6 Months
-11.26%
0%
-11.26%
1 Year
-11.81%
0%
-11.81%
2 Years
-5.28%
0%
-5.28%
3 Years
-12.24%
0%
-12.24%
4 Years
-33.86%
0%
-33.86%
5 Years
-38.77%
0%
-38.77%
Seikagaku Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.47%
EBIT Growth (5y)
-272.84%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
0.50
Tax Ratio
37.14%
Dividend Payout Ratio
134.86%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.20%
ROE (avg)
4.08%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.58
EV to EBIT
-12.29
EV to EBITDA
-106.20
EV to Capital Employed
0.49
EV to Sales
0.81
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3.97%
ROE (Latest)
-0.83%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
9,711.00
9,024.00
7.61%
Operating Profit (PBDIT) excl Other Income
565.00
449.00
25.84%
Interest
1.00
6.00
-83.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
354.00
890.00
-60.22%
Operating Profit Margin (Excl OI)
-2.60%
-8.80%
0.62%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 7.61% vs -1.69% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -60.22% vs 107.46% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
36,645.00
39,374.00
-6.93%
Operating Profit (PBDIT) excl Other Income
1,505.00
3,329.00
-54.79%
Interest
9.00
4.00
125.00%
Exceptional Items
-169.00
0.00
Consolidate Net Profit
1,473.00
1,214.00
21.33%
Operating Profit Margin (Excl OI)
-16.10%
33.90%
-5.00%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is -6.93% vs 8.73% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 21.33% vs -44.46% in Mar 2025
About Seikagaku Corp. 
Seikagaku Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






